Adjunct Professor, Joseph Cappelleri, celebrates 20 years with Pfizer

The Department of Biostatistics joins Pfizer in celebrating Adjunct Professor, Joseph Cappelleri, PhD, on 20 years of service.

Dr. Cappelleri was appointed Adjunct Professor by Brown’s Department of Biostatistics in 2012.  Since that time, he has been a regular speaker and mentor to Department students, providing career seminars focusing on the work of biostatisticians in industry.

Dr. Cappelleri joined Pfizer in June of 1996, as a statistical scientist, collaborating with Outcomes Research, and has since contributed in major ways across diverse therapeutic areas.  As a senior director in SCORAD, his current assignments include support for products in Pain, Inflammation, Oncology and other categories.

With over 350 publications, and at least twice as many co-authored conference presentations, Dr. Cappelleri has been the most published author in the history of Pfizer. His direct contributions to Pfizer have been prodigious with influential strategic and scientific impact, both internally and externally. To mention just a few examples, his co-authored presentation on patient preferences associated with therapies for rheumatoid arthritis (in support of tofacinitib), which was subsequently published, recently earned a platinum award from the Academy of Managed Care Pharmacy for its superior scientific content.  Earlier, another co-authored paper in support of Geodon on the meta-analysis of antipsychotic-induced weight gain has boasted more than 1,300 journal citations and is in the top five most frequently cited articles in the history of the American Journal of Psychiatry.

Dr. Cappelleri has also made many other noteworthy achievements with large impact in many areas, including development, psychometric validation and analysis patient-reported outcomes (PROs), real-world data analysis, and meta-analysis. Remarkably, his first 2 original publications on severity classes of erectile dysfunction (ED) using the International Index of Erectile Function (IIEF) (published in Urology) have merited more than 800 journal citations; these severity classes form the basis for efficacy assessment and a standard part of the inclusion criteria in innumerable trials for ED. His original publication on the IIEF-5 (International Journal of Impotence Research) has amassed more than 1250 journal citations. In addition, Joe has championed strategic initiatives and publications, with large impact, on the validation of primary and secondary outcomes in support of Chantix, Sutent, Lyrica, and other Pfizer medicines and compounds. Two of his publications on good clinical practices for network meta-analysis – which have been applied in support of Pfizer products – are among the most frequently cited in that field and in the journal in which they were published (Value in Health). According to ResearchGate, his work has been cited a total of 10,525 times.

Dr. Cappelleri has delivered numerous conference presentations and has published extensively on clinical and methodological topics, including regression-discontinuity design, which was used in the multi-billion Federal program “No Child Left Behind”, health measurement scales, and meta-analysis. In particular, he has been involved with research and applications on meta-analysis for almost 25 years and is an associate editor for the journal Research Synthesis Methods. He has also served on several other editorial boards and has reviewed for approximately 60 different journals. In addition, he is lead author of the book: Patient-Reported Outcomes: Measurement, Implementation and Interpretation, co-authored with other SCORAD colleagues.

Dr. Cappelleri earned his M.S. in statistics from the City University of New York (Baruch College), Ph.D. in psychometrics from Cornell University, and M.P.H. in epidemiology from Harvard University. In addition to his service as an adjunct faculty member at Brown University, he has also served as adjunct professor at the University of Connecticut and Tufts Medical Center. Recognized internationally for his work on patient-reported outcomes, he was invited for brief periods as a visiting scholar at Johns Hopkins University (Bloomberg School of Public Health) and guest faculty at the Mayo Clinic. As an executive committee member of the American Statistical Association, he has served as Chair of its Health Policy Statistics Section. Dr. Cappelleri is a Fellow of the American Statistical Association.

Congratulations, Dr. Cappelleri!